Potz Brittany A, Sellke Frank W, Abid M Ruhul
Cardiovascular Research Center, Division of Cardiothoracic Surgery, Department of Surgery, Rhode Island Hospital, Brown University Warren Alpert Medical School, USA.
J Intensive Crit Care. 2016;2(1). doi: 10.21767/2471-8505.100020. Epub 2016 Feb 29.
Sepsis is known as the presence of a Systemic Inflammatory Response Syndrome (SIRS) in response to an infection. In the USA alone, 750,000 cases of severe sepsis are diagnosed annually. More than 70% of sepsis-related deaths occur due to organ failure and more than 50% of septic patients demonstrate cardiac dysfunction. Patients with sepsis who develop cardiac dysfunction have significantly higher mortality, and thus cardiac dysfunction serves as a predictor of survival in sepsis. We have very little understanding about the mechanisms that result in cardiac dysfunction in the setting of sepsis. At present, the factors involved in sepsis-related cardiac dysfunction are believed to include the following: persistent inflammatory changes in the vascular endothelium and endocardium leading to circulatory and micro vascular changes, increase in endothelial reactive oxygen species (ROS), abnormal endothelium-leukocyte interaction resulting in a feed-forward loop for inflammatory cytokines and ROS, contractile dysfunction of the heart due to autonomic dysregulation, metabolic changes in myocardium leading to impaired oxygen delivery and increased oxygen consumption, mitochondrial dysfunction, and persistent inflammatory signaling. In this review article, we will briefly discuss the clinical challenges and our current understanding of cardiac dysfunction in sepsis. Major focus will be on the pathological changes that occur in vascular endothelium, with an emphasis on endocardium, and how endothelial ROS, impaired endothelium-leukocyte interaction, and microcirculatory changes lead to cardiac dysfunction in sepsis. The importance of the ongoing quest for the clinical biomarkers for cardiac dysfunction will also be discussed.
脓毒症被定义为因感染而出现的全身炎症反应综合征(SIRS)。仅在美国,每年就有75万例严重脓毒症被确诊。超过70%的脓毒症相关死亡是由器官衰竭导致的,超过50%的脓毒症患者存在心脏功能障碍。发生心脏功能障碍的脓毒症患者死亡率显著更高,因此心脏功能障碍是脓毒症患者生存的一个预测指标。我们对脓毒症时导致心脏功能障碍的机制了解甚少。目前,脓毒症相关心脏功能障碍涉及的因素被认为包括以下方面:血管内皮和心内膜持续的炎症变化导致循环和微血管改变、内皮活性氧(ROS)增加、内皮-白细胞异常相互作用导致炎症细胞因子和ROS的正反馈循环、自主神经调节异常导致的心脏收缩功能障碍、心肌代谢变化导致氧输送受损和氧消耗增加、线粒体功能障碍以及持续的炎症信号传导。在这篇综述文章中,我们将简要讨论脓毒症时心脏功能障碍的临床挑战以及我们目前的认识。主要重点将放在血管内皮发生的病理变化上,重点是心内膜,以及内皮ROS、内皮-白细胞相互作用受损和微循环变化如何导致脓毒症时的心脏功能障碍。还将讨论不断寻求心脏功能障碍临床生物标志物的重要性。